[Conventional Synthetic Disease-modifying Antirheumatic Drugs (DMARDs) for the Treatment of Non-infectious Uveitis].
Klin Monbl Augenheilkd. 2018.
PMID: 29739025
German.
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2018 | 2 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 1 |
| 2026 | 0 |
Search Results
7 results
Results by year
Citations
1
article
found by citation matching
Search results
Page 1
[Conventional Synthetic Disease-modifying Antirheumatic Drugs (DMARDs) for the Treatment of Non-infectious Uveitis].
Klin Monbl Augenheilkd. 2018 May;235(5):562-567. doi: 10.1055/a-0586-3931. Epub 2018 May 8.
Klin Monbl Augenheilkd. 2018.
PMID: 29739025
German.
The first-line therapy of uveitis normally consists of topical and/or systemic corticosteroid use. To achieve long-term ocular quiescence, to prevent uveitic secondary complications, to allow corticosteroid sparing and to avoid corticosteroid-related adverse effects …
The first-line therapy of uveitis normally consists of topical and/or systemic corticosteroid use. To achieve long-term ocular …
Update on the systemic management of noninfectious uveitis in children and adolescents.
Surv Ophthalmol. 2024 Jan-Feb;69(1):103-121. doi: 10.1016/j.survophthal.2023.01.002. Epub 2023 Jan 19.
Surv Ophthalmol. 2024.
PMID: 36682467
Review.
Treatment includes local and systemic approaches and this review will focus on systemic therapies that encompass corticosteroids, conventional synthetic disease-modifying antirheumatic drugs (csDMARD), and biological disease …
Treatment includes local and systemic approaches and this review will focus on systemic therapies that encompass corticosteroids, …
Treatment exit options for non-infectious uveitis registry: participant characteristics at 3 years.
Br J Ophthalmol. 2024 Dec 17;109(1):27-33. doi: 10.1136/bjo-2023-324927.
Br J Ophthalmol. 2024.
PMID: 38857972
PURPOSE: The Treatment exit Options For non-infectious Uveitis (TOFU) registry documents disease courses for non-anterior non-infectious uveitis entities with and without treatment to generate more evidence for clinic …
PURPOSE: The Treatment exit Options For non-infectious Uveitis (TOFU) registry documents disease courses …
[Therapeutic Concepts for Treatment of Patients with Non-infectious Uveitis Biologic Disease Modifying Antirheumatic Drugs].
Klin Monbl Augenheilkd. 2018 May;235(5):553-561. doi: 10.1055/a-0577-8006. Epub 2018 Apr 12.
Klin Monbl Augenheilkd. 2018.
PMID: 29649840
German.
Biologic disease modifying antirheumatic drugs (bDMARDs) can be highly efficient in the treatment of various non-infectious uveitis entities. Currently, the TNF-alpha-inhibitor Adalimumab is the only in-label therapeutic opt …
Biologic disease modifying antirheumatic drugs (bDMARDs) can be highly efficient in the treatment of vari …
Impact of biological therapy in reducing the risk of arthritis development in inflammatory bowel diseases.
RMD Open. 2024 Jan 31;10(1):e003820. doi: 10.1136/rmdopen-2023-003820.
RMD Open. 2024.
PMID: 38296800
Free PMC article.
OBJECTIVE: Evaluate spondyloarthritis (SpA) incidence in inflammatory bowel diseases (IBD) between patients treated with biological disease-modifying antirheumatic drugs (bDMARDs) and conventional DMARDs (cDMARDs) and define risk factors …
OBJECTIVE: Evaluate spondyloarthritis (SpA) incidence in inflammatory bowel diseases (IBD) between patients treated with biological disea …
Efficacy of TNF-Alpha Inhibitors to Control Inflammation and Prevent Secondary Complications in Non-Infectious Uveitis: A Real-Life Experience from Switzerland.
Ocul Immunol Inflamm. 2024 Oct;32(8):1585-1590. doi: 10.1080/09273948.2023.2263095. Epub 2023 Oct 5.
Ocul Immunol Inflamm. 2024.
PMID: 37797183
PURPOSE: To evaluate the efficacy of systemic tumor necrosis factor-alpha inhibitors (TNFi) in the treatment of non-infectious uveitis (NIU). METHODS: This Swiss multicenter retrospective cohort study included patients with NIU requiring TNFi during th …
PURPOSE: To evaluate the efficacy of systemic tumor necrosis factor-alpha inhibitors (TNFi) in the treatment of non-infecti …
Biological Agents' Adverse Events in Jordanian Childhood Rheumatic Diseases: A Single-Center Experience.
Cureus. 2025 Jan 28;17(1):e78122. doi: 10.7759/cureus.78122. eCollection 2025 Jan.
Cureus. 2025.
PMID: 40018478
Free PMC article.
Data collected and reviewed included demographic characteristics, diagnosis, concomitant use of disease-modifying conventional synthetic antirheumatic drugs (csDMARD), indications for starting biological agents, age at initiation o …
Data collected and reviewed included demographic characteristics, diagnosis, concomitant use of disease-modifying conventio …
Cite